UNSPSC 51241707: Boric acid/sodium chloride

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP400. This VA Drug Class (OP400) classifies this compound as belonging to the group CONTACT LENS SOLUTIONS.

UNSPSC 51241707 Boric acid/sodium chloride is a Commodity code that, based on recent state and local solicitations, encompasses generic multi-source pharmaceuticals and over-the-counter products distributed through cooperative purchasing arrangements to state and local government facilities. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, is the primary issuing body visible in current activity, procuring comprehensive pharmaceutical product lines with specific National Drug Codes (NDCs), SKUs, and packaging configurations for delivery through authorized wholesalers including AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC. Vendors must certify compliance with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), maintain contractual relationships with at least two of the three authorized wholesalers with chargeback systems in place, and demonstrate pricing flexibility through flat price, net price formats, or WAC-minus structures. All products must be available in the marketplace by May 15, 2026, and comply with FDA requirements with expiration dates of at least one year from manufacture and a minimum six-month shelf life.

The most recent opportunity is MMCAP's RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products, posted January 20, 2026, with proposals due March 26, 2026, establishing multiple contracts effective July 1, 2026 with a two-year initial term and optional extensions. The procurement extends across participating state and local government facilities in Minnesota and Oregon. Evaluation weighted price competitiveness at 75 percent, with fixed pricing (10 percent), price format compliance (5 percent), EDI capability (5 percent), and administrative fee agreement (5 percent) comprising the remainder. Vendors must maintain comprehensive insurance including $5,000,000 commercial general liability per occurrence, $2,000,000 network security and privacy liability, and $2,000,000 professional liability. No specific set-aside designations or restrictions limiting responses to particular business classifications are identified in the available documentation. The RFP structure reserves the right for sole, dual, or multi-awards based on therapeutic considerations, product availability, patient safety, and member-specific needs.